Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

277 results about "Thermal ablation" patented technology

Thermal ablation. Destruction of tissue by heating it (as with a microwave or radiofrequency energy) to temperatures at which cells cannot survive.

High frequency thermal ablation of cancerous tumors and functional targets with image data assistance

This invention relates to the destruction of pathological volumes or target structures such as cancerous tumors or aberrant functional target tissue volumes by direct thermal destruction. In the case of a tumor, the destruction is implemented in one embodiment of the invention by percutaneous insertion of one or more radiofrequency probes into the tumor and raising the temperature of the tumor volume by connection of these probes to a radiofrequency generator outside of the body so that the isotherm of tissue destruction enshrouds the tumor. The ablation isotherm may be predetermined and graded by proper choice of electrode geometry and radiofrequency (rf) power applied to the electrode with or without temperature monitoring of the ablation process. Preplanning of the rf electrode insertion can be done by imaging of the tumor by various imaging modalities and selecting the appropriate electrode tip size and temperature to satisfactorily destroy the tumor volume. Computation of the correct three-dimensional position of the electrode may be done as part of the method, and the planning and control of the process may be done using graphic displays of the imaging data and the rf ablation parameters. Specific electrode geometries with adjustable tip lengths are included in the invention to optimize the electrodes to the predetermined image tumor size.
Owner:COVIDIEN AG

Heart wall ablation/mapping catheter and method

Steerable electrophysiology catheters for use in mapping and / or ablation of accessory pathways in myocardial tissue of the heart wall and methods of use thereof are disclosed. The catheter comprises a catheter body and handle, the catheter body having a proximal section and a distal section and manipulators that enable the deflection of a distal segment of the distal tip section with respect to the independently formed curvature of a proximal segment of the distal tip section through a bending or knuckle motion of an intermediate segment between the proximal and distal segments. A wide angular range of deflection within a very small curve or bend radius in the intermediate segment is obtained. At least one distal tip electrode is preferably confined to the distal segment which can have a straight axis extending distally from the intermediate segment. The curvature of the proximal segment and the bending angle of the intermediate segment are independently selectable. The axial alignment of the distal segment with respect to the nominal axis of the proximal shaft section of the catheter body can be varied between substantially axially aligned (0° curvature) in an abrupt knuckle bend through a range of about −90° to about +180° within a bending radius of between about 2.0 mm and 7.0 mm and preferably less than 5.0 mm. The proximal segment curve can be independently formed in a about +180° through about +270° with respect to the axis of the proximal shaft section to provide an optimum angular orientation of the distal electrode(s). The distal segment can comprise a highly flexible elongated distal segment body and electrode(s) that conform with the shape and curvature of the heart wall.
Owner:MEDTRONIC INC

Prostatic stent with localized tissue engaging anchoring means and methods for inhibiting obstruction of the prostatic urethra

A prostatic stent is configured as a unitary body which is adapted to reside above the sphincter when in position in the subject includes an elongated tube which extends through the sphincter and outside the body of the subject. The stent is configured to allow natural operation of the sphincter when in position in the subject. The unitary body stent includes a lower inflatable portion which expands to contact tissue and help hold the stent in a desired location during a chronic use period of about 2-14 days. The stent can also include an upper and/or intermediate inflatable portions. A method of inhibiting the obstruction or closure of the prostatic urethral opening includes positioning the stent in the subject such that the unitary body of the stent is in the prostate and resides above the sphincter. A method treating BPH includes thermally ablating localized tissue in the prostate and inserting a post-treatment catheter into the prostate (preferably after an initial healing period) to allow the treated tissue to contour therearound and to maintain the urinary passage open. The stent is configured as a unitary body stent adapted to reside above the sphincter of the subject and to allow substantially normal operation of the sphincter. The stent can include a lower inflatable portion which engages, when expanded, with tissue below the localized treatment region about the membranous urethra (between the sphincter and the verumontanum). The post-treatment catheter is configured to reside in the subject for a period of about 2-14 days after delivery of the thermal ablation treatment or therapy.
Owner:JPMORGAN CHASE BANK AS ADMINISTATIVE AGENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products